adenoviral tumor-specific neoantigen priming vaccine GRT-C901

{
  "id": "MLC-T-ONC-009678",
  "term": "adenoviral tumor-specific neoantigen priming vaccine GRT-C901",
  "field": "Oncology and biomedicine",
  "definition": "A personalized cancer vaccine comprised of a chimpanzee adenovirus vector (ChAdV) encoding twenty tumor-specific neoantigens (TSNAs) that have been identified through genetic sequencing of a patient’s tumor cells, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of the adenoviral-TSNA priming vaccine GRT-C901, the adenovirus infects cells and expresses the TSNAs. This stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TSNAs, leading to tumor cell lysis. Adenoviral-TSNA vaccine GRT-C901 is followed by monthly boosting with a self-amplifying mRNA (SAM) boosting vaccine that encodes the same 20 target TSNAs. The combined immunotherapy product, consisting of priming and boosting vaccines, is referred to as GRANITE-001.",
  "synonyms": [
    "adenoviral TSNA priming vaccine GRT-C901"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/adenoviral-tumor-specific-neoantigen-priming-vaccine-grt-c901/"
}